000 03966nam a22004215i 4500
999 _c391116
_d391116
001 391116
003 ES-MaUEC
005 20230522214833.0
006 a|||| o|||| 00| 0
007 cr nn 008mamaa
008 230512s1987 xxu| o |||| 0|eng d
020 _a9781603274067
024 7 _a10.1007/978-1-60327-406-7
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aQH585.5.F56
_b1987 EB
100 1 _aGray, Joe W.
_eautor
_4aut
_4http://id.loc.gov/vocabulary/relators/aut
_9688489
245 1 0 _aTechniques in Cell Cycle Analysis
_cby Joe W. Gray, Zbigniew Darzynkiewicz
250 _a1st edition 1987
264 1 _aTotowa, NJ
_bHumana Press
_c1987
300 _a1 recurso en línea (XVIII, 407 páginas)
_b97 ilustraciones
336 _atexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
490 0 _aBiological Methods
505 0 _aAutoradiographic Techniques for Measurement of the Labeling Index -- Percent Labeled Mitosis Curve Analysis -- Tumor Growth Fraction Estimation, Perturbation, and Prognostication -- In Vitro Assays for Tumors Grown In Vivo -- Flow Cytokinetics -- Solid Tissue Dispersal for Cytokinetic Analyses -- Multivariate Cell Analysis -- Data Analysis in Cell Kinetics Research -- Cytochemical Probes of Cycling and Quiescent Cells Applicable to Flow Cytometry -- Assay of Cell Cycle Kinetics by Multivariate Flow Cytometry Using the Principle of Stathmokinesis -- Flow Cytometric Studies on Intracellular Drug Fluorescence -- Cell Synchrony Techniques.
520 _aQuantification of the proliferative characteristics of normal and malignant cells has been of interest to oncolo­ gists and cancer biologists for almost three decades. This interest stems from (a) the fact that cancer is a disease of uncontrolled proliferation, (b) the finding that many of the commonly used anticancer agents are preferentially toxic to cells that are actively proliferating, and (c) the observa­ tion that significant differences in proliferation characteristics exist between normal and malignant cells. Initially, cell cycle analysis was pursued enthusiastically in the hope of gener­ ating information useful for the development of rational cancer therapy strategies; for example, by allowing identi­ fication of rapidly proliferating tumors against which cell cycle-specific agents could be used with maximum effec­ tiveness and by allowing rational scheduling of cell cyc- specific therapeutic agents to maximize the therapeutic ratio. Unfortunately, several difficulties have prevented realiza­ tion of the early promise of cell cycle analysis: Proliferative patterns of the normal and malignant tissues have been found to be substantially more complex than originally an­ ticipated, and synchronization of human tumors has proved remarkably difficult. Human tumors of the same type have proved highly variable, and the cytokinetic tools available for cell cycle analysis have been labor intensive, as well as somewhat subjective and in many cases inapplicable to humans. However, the potential for substantially improved cancer therapy remains if more accurate cytokinetic infor­ mation about human malignancies and normal tissues can be obtained in a timely fashion.
988 _aSpringer_Protocols_1987
650 7 _2embne
_9668358
_aCitometría de flujo
700 1 _aDarzynkiewicz, Zbigniew
_eautor
_4aut
_4http://id.loc.gov/vocabulary/relators/aut
_9688490
776 0 8 _iPrinted edition:
_z9781489941015
776 0 8 _iPrinted edition:
_z9781489941008
776 0 8 _iPrinted edition:
_z9780896030978
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-1-60327-406-7
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b05/2023
_dz
_eIG
_zSI